Evidence map›Paper›PMID 41393996›Full record

ArticleFrontiers in neurology2025

Clinical characteristics of myasthenia gravis patients with coexistence of AChR and titin antibodies.

Siqi Wang, Difang Shi, Shanshan Wu, Qijie Zhang, Weiwei Xiao, Fang Qian, Yan Zheng, Jianjian Bao, Jia Liu, Xujun Chu and 1 more

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Siqi Wang *Department of Clinical Pharmacy, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Difang Shi *Department of Thoracic Surgery I, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China.
Shanshan Wu *Department of Clinical Pharmacy, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Qijie ZhangDepartment of Neurology, Qujing Second People's Hospital, Qujing, Yunnan, China.
Weiwei XiaoDepartment of Neurology, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Fang QianDepartment of Neurology, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Yan ZhengDepartment of Neurology, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Jianjian BaoDepartment of Neurology, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Jia LiuDepartment of Neurology, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Xujun ChuDepartment of Neurology, The Affiliated Shandong Provincial Hospital of Shandong First Medical University, Jinan, Shandong, China.
Kang DuDepartment of Neurology, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to investigate the clinical characteristics of patients with myasthenia gravis (MG) who are double-seropositive for acetylcholine receptor antibodies (AChR-Ab Methods: A retrospective analysis was conducted on MG patients hospitalized in the Department of Neurology between March 2020 and June 2024. Patients were categorized into two groups based on antibody profiles: those with AChR antibody positivity alone and those with dual positivity for AChR and titin antibodies. Clinical features, MG classification, and treatment outcomes were compared between the two groups. Results: A total of 35 MG patients were included, comprising 18 with single AChR-Ab Conclusion: This study provides the first systematic characterization of the clinical profile of AChR-Ab

Indexed as

AChR and titin antibodymyasthenia gravisSouthwest Chinathymomathyroid function

Identifiers

PMID41393996
PMCPMC12698476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.